Detalles de la búsqueda
1.
Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
Am Heart J
; 232: 71-83, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33157067
2.
Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions.
J Vasc Surg
; 73(5): 1702-1714.e11, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33080324
3.
Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
J Endovasc Ther
; 28(2): 229-235, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084502
4.
Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
J Vasc Interv Radiol
; 29(1): 9-17.e1, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29122449
5.
A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.
J Endovasc Ther
; 24(4): 499-503, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28485182
6.
Navigating the Regulatory Pathway for Medical Devices-a Conversation with the FDA, Clinicians, Researchers, and Industry Experts.
J Cardiovasc Transl Res
; 15(5): 927-943, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35288821
7.
First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study.
Front Cardiovasc Med
; 9: 877578, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36237908
8.
Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
J Endovasc Ther
; 18(5): 613-23, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21992630
9.
Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute's Medical Technology Advance Program.
J Clin Transl Sci
; 5(1): e79, 2021 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34007464
10.
Erratum: Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute's Medical Technology Advance Program - ERRATUM.
J Clin Transl Sci
; 5(1): e131, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34367676
11.
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Cardiovasc Intervent Radiol
; 44(2): 196-206, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33025243
12.
Vascular Quality Initiative Surveillance of Femoropopliteal Artery Paclitaxel Devices.
JACC Cardiovasc Interv
; 14(23): 2598-2609, 2021 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887051
13.
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Cardiovasc Intervent Radiol
; 43(1): 8-19, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31502026
14.
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Cardiovasc Intervent Radiol
; 42(3): 358-364, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30411151
15.
Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
J Am Coll Cardiol
; 73(6): 667-679, 2019 02 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30765033
16.
Sustained abdominal compression during CPR raises coronary perfusion pressures as much as vasopressor drugs.
Resuscitation
; 75(3): 515-24, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17630090
17.
Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Cardiovasc Intervent Radiol
; 40(11): 1669-1677, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28488101
18.
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
JACC Cardiovasc Interv
; 9(3): 271-277, 2016 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26847118
19.
Zilver PTX RCT mortality analysis: no difference in long-term mortality rate for Zilver PTX drug-eluting stent compared to PTA/BMS.
CVIR Endovasc
; 2(1): 25, 2019 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32027000
20.
The natural biochemical changes during ventricular fibrillation with cardiopulmonary resuscitation and the onset of postdefibrillation pulseless electrical activity.
Am J Emerg Med
; 24(5): 577-81, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16938597
Resultados
1 -
20
de 20
1
Próxima >
>>